摘要
目的观察瑞舒伐他汀和阿托伐他汀对氯吡格雷抗血小板活性的影响。方法选择60例冠心病患者接受阿司匹林100mg/d、氯吡格雷75 mg/d及低分子肝素5000 U/12 h治疗,5 d后随机分为阿托伐他汀20mg/d(阿托伐他汀组,30例)和瑞舒伐他汀10 mg/d(瑞舒伐他汀组,30例)。在服用氯吡格雷之前(基线值)、加用他汀类药物之前及服用他汀类药物3d后,用全血阻抗法分别测定不同浓度二磷酸腺苷(5、10、20μmol/L)诱导的血小板聚集率。结果与基线值比较,服用氯吡格雷5 d后和加服他汀类药物治疗3 d后,2组患者血小板聚集率明显降低,差异有统计学意义(P<0.05);与治疗前比较,阿托伐他汀组患者血小板聚集率有所升高,而瑞舒伐他汀组患者血小板聚集率有所下降,但差异无统计学意义(P>0.05)。结论经细胞色素3A4途径代谢的阿托伐他汀及不经细胞色素3A4代谢的瑞舒伐他汀,短期内对氯吡格雷抗血小板活性无影响。
Objective To observe the influence of rosuvastatin or atorvastatin on platelet aggrega- tion in patients treated with clopidogrel. Methods A total of 60 hospitalized patients with coronary heart disease received antiplatelet and anticoagulation treatment including aspirin 100 rag/d, clopidogrel 75 mg/d,and low molecular weight heparin 5000 U/12 h. Five days after receiving the above medication,the patients were randomized to atorvastatin 20 mg/d treatment group（Group A, n = 30）,and rosuvastatin 10 mg/d treatment group（Group R, n = 30）. Platelet aggregation induced by adenosine diphosphate（ADP） 5,10,and 20 μmol/L was measured with whole blood impedance method on the day before clopidogrel therapy（baseline）,the day before statin therapy, and 3 days after statin therapy. Results ADP-induced platelet aggregation was significantly de- creased by clopidogrel therapy （P 〈 0.05） ,but no statistical difference was observed under addi- tional treatment with atorvastatin or rosuvastatin （P〉0.05）. Conclusion Neither atorvastatin nor rosuvastatin attenuates the antiplatelet effects of clopidogrel during short-term co-medication.
出处
《中华老年心脑血管病杂志》
CAS
北大核心
2011年第1期27-29,共3页
Chinese Journal of Geriatric Heart,Brain and Vessel Diseases
关键词
血小板聚集抑制剂
阿司匹林
肝素
腺苷二磷酸
细胞色素类
血小板聚集
冠心病
platelet aggregation inhibitors
aspirin
heparin
adenosine diphosphate
cytochromes
platelet agregation
coronary disease
